Literature DB >> 32228982

Hemolysis tendency of anticancer nanoparticles changes with type of blood group antigen: An insight into blood nanoparticle interactions.

Nimisha Singh1, Suban K Sahoo1, Rajender Kumar2.   

Abstract

Different blood groups of ABO system have specific antigen which bestows them with different biochemical properties and hence they can show different hemolytic activity. In this report, hemolytic activity of thiol-functionalized Fe3O4-Au nanoparticles were studied in presence and absence of doxorubicin and the effect of various thiol coatings were correlated towards their hemolysis tendency. The nanoparticles were functionalized with four different amino thiols, cysteamine (CEA), cystamine (CA), cysteine (Cys) and cystine (Cyt) to form Fe3O4-Au CEA, Fe3O4-Au CA, Fe3O4-Au Cys and Fe3O4-Au Cyt nanoparticles which were loaded with anticancer drug, doxorubicin. The functionalization was characterized using ATR-FTIR, HR-TEM, XPS and other spectroscopic methods. Maximum drug encapsulation efficiency of 83% was observed with Fe3O4-Au CA nanoparticles. In-vitro experiments were performed on HeLa cells to check the cellular uptake and cytotoxicity using MTT assay. Hemolytic activity was then analyzed with all the blood groups (positive and negative). The amino acid functionalized, Fe3O4-Au Cys and Fe3O4-Au Cyt nanoparticles, shows lesser hemolysis compared to amino thiol functionalized Fe3O4-Au CEA, and Fe3O4-Au CA nanoparticles. In positive blood groups, the Fe3O4-Au CA nanoparticles shows the highest rate of hemolysis followed by Fe3O4-Au CEA, while the lowest hemolysis rate was observed for Fe3O4-Au Cyt nanoparticles. For negative blood groups, the thiol coated nanoparticles show more abrupt hemolysis rate depending upon the type of antigen.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ABO system; Anticancer; Antigen; Hemolysis; Nanocarrier

Mesh:

Substances:

Year:  2020        PMID: 32228982     DOI: 10.1016/j.msec.2020.110645

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  3 in total

1.  Evaluation of the Hemocompatibility and Anticancer Potential of Poly(ε-Caprolactone) and Poly(3-Hydroxybutyrate) Microcarriers with Encapsulated Chrysin.

Authors:  Eleftherios Halevas; Chrysoula Kokotidou; Elda Zaimai; Alexandra Moschona; Efstratios Lialiaris; Anna Mitraki; Theodore Lialiaris; Anastasia Pantazaki
Journal:  Pharmaceutics       Date:  2021-01-16       Impact factor: 6.321

2.  Oxidation and Reduction Dual-Responsive Polymeric Prodrug Micelles Co-delivery Precisely Prescribed Paclitaxel and Honokiol for Laryngeal Carcinoma Combination Therapy.

Authors:  Lanzhu Zhou; Jun Wu; Zhe Sun; Wenzhong Wang
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

3.  Biosynthesis of silver nanoparticles using Haloferax sp. NRS1: image analysis, characterization, in vitro thrombolysis and cytotoxicity.

Authors:  Hend M Tag; Amna A Saddiq; Monagi Alkinani; Nashwa Hagagy
Journal:  AMB Express       Date:  2021-05-26       Impact factor: 3.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.